Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
07 February 2024 - 10:40PM
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical
biopharmaceutical company focused on the discovery, development,
and commercialization of drugs for the treatment of cancer, today
announced that James Caruso, president and chief executive officer
of Cellectar, will present an overview of the company at the
upcoming Oppenheimer 34th Annual Healthcare Life Sciences
Conference being held virtually. Details of the presentation are as
follows:
Date: |
|
Wednesday,
February 14, 2024 |
Time: |
|
2:00 – 2:30 pm Eastern Time |
Webcast: |
|
Click HERE |
A replay of the presentation will be available on Events section
of the company’s investor relations website.
About Cellectar Biosciences,
Inc.Cellectar Biosciences is a late-stage clinical
biopharmaceutical company focused on the discovery and development
of proprietary drugs for the treatment of cancer, independently and
through research and development collaborations. The company’s core
objective is to leverage its proprietary Phospholipid Drug
Conjugate™ (PDC) delivery platform to develop the next-generation
of cancer cell-targeting treatments, delivering improved efficacy
and better safety as a result of fewer off-target effects.
The company’s product pipeline includes lead
asset iopofosine I 131, a small-molecule PDC designed to provide
targeted delivery of iodine-131 (radioisotope), proprietary
preclinical PDC chemotherapeutic programs and multiple partnered
PDC assets.
For more information, please visit
www.cellectar.com and www.wmclinicaltrial.com or join the
conversation by liking and following us on the company’s social
media channels: Twitter, LinkedIn, and Facebook.
Contacts
MEDIA:Claire LaCagninaBliss Bio
Health315-765-1462clacagnina@blissbiohealth.com
INVESTORS:Chad KoleanChief Financial
Officerinvestors@cellectar.com
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Sep 2024 to Oct 2024
Cellectar Biosciences (NASDAQ:CLRB)
Historical Stock Chart
From Oct 2023 to Oct 2024